Medical Management
Applied
Type
ModificationConfidence
90%
Created
Apr 19, 2026
Evidence
1 source
Rationale
The 2024 ACC/AHA Lower Extremity PAD Guideline (PMID 38743805) directly supersedes the 2016 AHA guideline for recommendations on blood pressure control and glycemic management in PAD patients. Per the stale guideline replacement instructions, [@aha2016] has been replaced with [@svs2024-gornik] for the blood pressure and glycemic control claim. No other content changes are warranted, as the remaining citations and text are not contradicted by the new guideline and the section's existing structure and density are preserved.
Evidence
Content Changes
- Lifestyle modification: Smoking cessation reduces abdominal aortic aneurysm (AAA) expansion and peripheral arterial disease (PAD) progression (Golledge 2017)📄. Exercise therapy improves walking distance in PAD. Comprehensive risk factor modification, including diet and physical activity, remains the cornerstone of cardiovascular prevention (Al 2025).
- Antiplatelet therapy: Aspirin or clopidogrel for secondary prevention in symptomatic atherosclerotic disease (CAPRIE 1996).
- Anticoagulation: Low-dose rivaroxaban plus aspirin benefits select PAD patients; see 10Ch. 10 for COMPASS/VOYAGER-PAD evidence and patient selection criteria.
- Lipid lowering: High-intensity statins reduce events and slow aneurysm growth (Al 2025). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide additional risk reduction in statin-intolerant or high-risk patients (Sabatine 2017)📄.
- Blood pressure and glycemic control: Angiotensin-converting enzyme (ACE) inhibitors and tight glycemic control improve vascular outcomes (AHA 2024). In patients with diabetes and PAD, management requires intensive risk factor control and the use of evidence-based glucose-lowering therapies to reduce the risk of major adverse limb and cardiovascular events (Das 2025).
- Risk stratification: In patients with established atherosclerotic cardiovascular disease (ASCVD), the SMART2-HF model can be utilized to predict the risk of incident heart failure, facilitating early intervention and personalized management (Reitsma 2026).
Before
- Lifestyle modification: Smoking cessation reduces abdominal aortic aneurysm (AAA) expansion and peripheral arterial disease (PAD) progression (Golledge 2017)📄. Exercise therapy improves walking distance in PAD. Comprehensive risk factor modification, including diet and physical activity, remains the cornerstone of cardiovascular prevention (Al 2025).
- Antiplatelet therapy: Aspirin or clopidogrel for secondary prevention in symptomatic atherosclerotic disease (CAPRIE 1996).
- Anticoagulation: Low-dose rivaroxaban plus aspirin benefits select PAD patients; see 10Ch. 10 for COMPASS/VOYAGER-PAD evidence and patient selection criteria.
- Lipid lowering: High-intensity statins reduce events and slow aneurysm growth (Al 2025). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide additional risk reduction in statin-intolerant or high-risk patients (Sabatine 2017)📄.
- Blood pressure and glycemic control: Angiotensin-converting enzyme (ACE) inhibitors and tight glycemic control improve vascular outcomes (Patel 2016)📄. In patients with diabetes and PAD, management requires intensive risk factor control and the use of evidence-based glucose-lowering therapies to reduce the risk of major adverse limb and cardiovascular events (Das 2025).
- Risk stratification: In patients with established atherosclerotic cardiovascular disease (ASCVD), the SMART2-HF model can be utilized to predict the risk of incident heart failure, facilitating early intervention and personalized management (Reitsma 2026).
After
- Lifestyle modification: Smoking cessation reduces abdominal aortic aneurysm (AAA) expansion and peripheral arterial disease (PAD) progression (Golledge 2017)📄. Exercise therapy improves walking distance in PAD. Comprehensive risk factor modification, including diet and physical activity, remains the cornerstone of cardiovascular prevention (Al 2025).
- Antiplatelet therapy: Aspirin or clopidogrel for secondary prevention in symptomatic atherosclerotic disease (CAPRIE 1996).
- Anticoagulation: Low-dose rivaroxaban plus aspirin benefits select PAD patients; see 10Ch. 10 for COMPASS/VOYAGER-PAD evidence and patient selection criteria.
- Lipid lowering: High-intensity statins reduce events and slow aneurysm growth (Al 2025). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide additional risk reduction in statin-intolerant or high-risk patients (Sabatine 2017)📄.
- Blood pressure and glycemic control: Angiotensin-converting enzyme (ACE) inhibitors and tight glycemic control improve vascular outcomes (AHA 2024). In patients with diabetes and PAD, management requires intensive risk factor control and the use of evidence-based glucose-lowering therapies to reduce the risk of major adverse limb and cardiovascular events (Das 2025).
- Risk stratification: In patients with established atherosclerotic cardiovascular disease (ASCVD), the SMART2-HF model can be utilized to predict the risk of incident heart failure, facilitating early intervention and personalized management (Reitsma 2026).